Thompson, Philip A. http://orcid.org/0000-0003-2086-6031
Keating, Michael J.
Ferrajoli, Alessandra
Jain, Nitin
Peterson, Christine B. http://orcid.org/0000-0003-3316-0468
Garg, Naveen
Wang, Sa A. http://orcid.org/0000-0001-9385-9911
Jorgensen, Jeffrey L. http://orcid.org/0000-0002-1875-2986
Kadia, Tapan M. http://orcid.org/0000-0002-9892-9832
Bose, Prithviraj http://orcid.org/0000-0002-4343-5712
Pemmaraju, Naveen http://orcid.org/0000-0002-1670-6513
Short, Nicholas J. http://orcid.org/0000-0002-2983-2738
Wierda, William G. http://orcid.org/0000-0002-7357-270X
Article History
Received: 25 December 2022
Revised: 29 March 2023
Accepted: 6 April 2023
First Online: 3 May 2023
Competing interests
: PT: Research support from AbbVie, Pharmacyclics, Lilly and Adaptive Biotechnologies; Advisory board/honoraria from Janssen, AbbVie, Adaptive Biotechnologies, Beigene, Lilly, Genentech. AF: Research support from Beigene and AstraZeneca; Advisory board/honoraria from Janssen, Beigene and AstraZeneca. NJ: Research support from Pharmacyclics, AbbVie, Genentech, AstraZeneca, BMS, Pfizer, Servier, ADC Therapeutics, Cellectis, Adaptive Biotechnologies, Incyte, Precision Biosciences, Aprea Therapeutics, Fate Therapeutics, Kite/Gilead, Mingsight, Takeda, Medisix, Loxo Oncology, Novalgen, Dialectic Therapeutics, Newave, TransThera Sciences, Novartis; Consulting/Honoraria from Pharmacyclics, Janssen, AbbVie, Genentech, AstraZeneca, BMS, Adaptive Biotechnologies, Kite/Gilead, Precision Biosciences, Beigene, Cellectis, TG Therapeutics, MEI Pharma, Ipsen, CareDX. TMK: Consulting: AbbVie, Agios, Daiichi Sankyo, Genetech, Genzyme, Jazz Pharmaceuticals, Liverum, Novartis, Pfizer, PinotBio, Pulmotect, Sanofi-Aventis, Servier; Research support: AbbVie, Amgen, Ascentage, Astellas, Astex, AstraZeneca, BMS, Celgene, Cellnkos, Cyclacel, Delta-Fly Pharmac, Genetech, Genfleet, Glycomimetics, Iterion, Janssen, Jazz, Pfizer, Pulmotect, Regeneron, SELLAS Life Sciences; Speaker’s Bureau: Biologicx, Cure, Hikma Pharmaceuticals. PB: Honoraria: Incyte, BMS, CTI, Sierra, GSK, Morphosys, Blueprint, Cogent, Novartis, Abbvie, Karyopharm, Pharma Essentia; Research support: Incyte, BMS, CTI, Kartos, Morphosys, Blueprint, Cogent, Ionis, Astellas, Pfizer, NS Pharma and Promedior. NP: Board of Directors/Management: Dan’s House of Hope; Consulting: Protagonist Therapeutics, Cimeio Therapeutics AG, Immunogen, Pacylex Pharmaceuticals, MoreHealth, Cellectis, Stemline; Scientific/Advisory Committee Member: Incyte; Speaker/Preceptorship: Medscape, Intellisphere, LLC; Research Support: US Department of Defense (DOD). NJS: Consulting fees from Pfizer Inc., Jazz Pharmaceuticals, and Sanofi; Research funding from Takeda Oncology, Astellas Pharma Inc., Xencor and Stemline Therapeutics; honoraria from Novartis, Amgen, Astellas Pharma Inc., Sanofi and BeiGene. WGW: Research Support: GSK/Novartis, Abbvie, Genentech, Pharmacyclics LLC, AstraZeneca/Acerta Pharma, Gilead Sciences, Bristol Myers Squibb (Juno & Celgene), KITE Pharma, Sunesis, Miragen, Oncternal Therapeutics, Inc., Cyclacel, Loxo Oncology, Inc./Lilly, Janssen, Xencor.